HOLLISTER, Calif., Feb. 10, 2023 (GLOBE NEWSWIRE) -- Alpha Teknova, Inc. (“Teknova”) (Nasdaq: TKNO), a leading producer of critical reagents for the research, discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics, today announced that the Company will participate in the following upcoming investor conferences:
BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
February 14 - 16, 2023
Snowbird, UT
Cowen 43rd Annual Health Care Conference
March 6 - 8, 2023
Boston, MA
Fireside Chat: Wednesday, March 8, 2023, at 2:10 p.m. EST
Stephen Gunstream, Teknova’s President and Chief Executive Officer, and Matt Lowell, Teknova’s Chief Financial Officer, plan to discuss Company highlights, their product portfolio, market trends, key growth drivers, and long-term market opportunities.
A live audio webcast from the Cowen 43rd Annual Health Care Conference may be accessed from the Investor Relations section of the Company’s website: https://ir.teknova.com/. Webcasts are available on the Company’s website for approximately 90 days after each event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been innovating the manufacture of critical reagents for the life sciences industry to accelerate the discovery and development of novel therapies that will help people live longer, healthier lives. We offer fully customizable solutions for every stage of the workflow, supporting industry leaders in cell and gene therapy, molecular diagnostics, and synthetic biology. Our fast turnaround of high-quality agar plates, microbial culture media, buffers and reagents, and water helps our customers scale seamlessly from RUO to GMP. Headquartered in Hollister, California, with over 400,000 square feet of state-of-the-art facilities, Teknova’s modular manufacturing platform was designed by our team of scientists, engineers, and quality control experts to efficiently produce the foundational ingredients for the discovery and commercialization of novel therapies.
| Last Trade: | US$7.06 |
| Daily Change: | -0.05 -0.70 |
| Daily Volume: | 137,828 |
| Market Cap: | US$376.300M |
August 13, 2024 July 12, 2024 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
